

The Mission Marketing Group

Building the healthcare offering

The mission has extended the range of its capabilities in the healthcare segment with the acquisition of RJW & Partners, announced this morning. RJW, a consultancy specialising in pricing and market access strategy, has a wide range of high-profile clients including AstraZeneca, Shire and Novartis. The purchase is for £1.75m (plus £0.23m for cash balances), payable 95% in cash, 5% in shares. Consensus forecasts indicate that it should enhance earnings in FY17e and FY18e by 3% and 4%, respectively. Mission's shares continue to trade at an unwarranted discount to its peers.

What's new?

Key priorities identified in last month's final results for FY16 were to back growth in existing agencies and increase exposure to faster growing areas, such as data and healthcare. This acquisition ticks both those last boxes. It is complementary to the existing mission Healthcare market offering, based around the Solaris agency, that specialises in medical marketing communications. RJW adds 30 employees, mainly in the UK but advising clients across global markets in the pharmaceutical and medical devices segments. The price is equivalent to 1.1x revenues to March 2016; 4.4x profits for that year. Results will be consolidated for around eight months of mission's FY17e figures, lifting consensus profit forecasts by 3% and by 5% for the full twelve months of FY18e. Up to a further £4.25m is payable across 2017-2020, subject to financial performance and in the same cash/equity ratio.

Balance sheet well under control

Paying for acquisitions predominantly in cash inevitably pushes back the time frame for debt reduction. Under the group targets, the debt KPI is for net bank debt/EBITDA to remain under 2.0x (FY16:1.3x) and total debt to EBITDA below 2.5x (FY16: 1.7x). With only a modest net cash outflow likely for the current year, even with this deal, there is still clearly plenty of headroom within these limits to continue the investment in order to continue to grow the business.

Valuation: Overstated discount

The mission continues to trade in a range of 38-47p, representing a substantial discount to other quoted marketing/communications businesses. The current price puts it on an FY17e EV/EBITDA of 4.5x, compared to the sector at 9.6x, a 53% discount; on a P/E basis its multiple of 5.7x compares to peers at 11.2x. The sizes of these discounts are difficult to justify given the earnings and dividend growth and the improved state of the balance sheet.

Consensus estimates							
Year end	Revenue (£m)	PBT (£m)	EPS (p)	DPS (p)	P/E (x)	Yield (%)	
12/15	61.0	6.5	5.9	1.2	7.0	2.9	
12/16	65.9	7.0	6.4	1.5	6.5	3.6	
12/17e	70.2	7.9	7.3	1.65	5.7	4.0	
12/18e	74.3	8.9	8.3	1.8	5.0	4.3	

Source: Company accounts, Bloomberg

Media

27 April 2017



Share price graph



Share details

Code	TMMG
Listing	AIM
Shares in issue	84.12m

Business description

The mission is a network of entrepreneurial marketing communications agencies predominantly in the UK, and also Asia and San Francisco. The group provides general, sector vertical, functional and geographic specialisms to national and international clients.

Bull

- Organic growth well ahead of market.
- Strengthening balance sheet.
- Progressive dividend.

Bear

- Geopolitical uncertainty.
- Client pressure on pricing/procurement.
- Bias to H2 limits visibility.

Analysts

Fiona Orford-Williams +44 (0)20 3077 5739

Bridie Barrett +44 (0)20 3077 5757

media@edisongroup.com

The Mission Marketing Group is a research client of Edison Investment Research Limited



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited (Edison Commission).

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australial by Edison Australian Corporations Act. The Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is sisted in Australial by Edison Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Securities and Exchange Commission. Edison Ous Testes upon the "publishers' exclusion" from the definition of investment adviser under Securities and Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advise